RAD51 and ovarian carcinoma: Previous studies have shown that overexpression of RAD51 in various cancers, including esophageal adenocarcinoma, colon cancer, breast cancer, and ovarian cancer, is associated with drug resistance, immune evasion, and a poor prognosis (11, 12).